TMB E38: Jeffrey Prather, Genetics, Robotics, Nanotech.

Jeffrey Prather: Businessman, Author, Actor, Broadcaster, Warrior4518 E Broadway, Tucson, AZ 85749520/[email protected],WarriorSchool.com,  BujinkanUSA.com. GRIN-X.comTucson business founder since 1990. Second since 1995. Third in 2014. All still going strong. Thought leader, business coach, radio host, life coach, skills teacher.Published author. Specializing in high-stakes strategic analysis, continuity of operations, human terrain, and competitive intelligence preparation of the market place. Martial arts master. World-class firearms instructor.Retired, disabled, Army veteran. Ex-DEA special agent. Former DIA Branch Chief. Chaplain. Adopted orphan. Dad. Husband.Inducted twice into the US Martial Arts Hall of Fame and featured in the US and Japanese martial arts magazines and published in tactical journalsGRIN-X is the intersection for Genetics, Robotics, Information, and Nanotechnology.Futurists predict that in the near-decade GRIN will completely transform the market space.Never before imagined products, therapies, technologies, and markets will emerge.Conventional regulations, traditional financing, and corporate models will be disrupted.BenefitsVia our corporate strategy and competitive intelligence services, we provide emerging technology pathfinders, key stakeholders, and visionary investors, a roadmap to navigate the human and business terrain, to achieve the successful emergence of new medicines, treatments, and technology products.Since 2014 every GRIN-X client exceeded goals. For exampleCancer Prevention Pharmaceuticals-2018In April 2018, UK-based Mallinckrodt had exercised its option to the license agreement and paid CPP $10 million to support the pivotal Phase 3 clinical trial of CPP-1X/sul in patients with the orphan disease familial adenomatous polyposis (FAP).Calimmune-2017Global biotherapeutics leader CSLBehring announced today that it has agreed to acquire Calimmune, Inc., a biotechnology company focused on the development of ex Vivo hematopoietic stem cell (HSC) gene therapy with R&D facilities in Pasadena, California and Sydney, Australia for an upfront payment of  $91 million, with possible milestone payments reaching an eventual total of $416 million.GRIN-X 520-241-7690 8987 E. Tanque Verde Rd St 309-245 Tucson, AZ 8574 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.